The DOI matches its Crossref record; 63 of the 70 references it cites were found in a registry or an index.
Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α
Open accessAbstract
The switch to an angiogenic phenotype is a fundamental determinant of neoplastic growth and tumor progression. We demonstrate that homozygous deletion of the p53 tumor suppressor gene via homologous recombination in a human cancer cell line promotes the neovascularization and growth of tumor xenografts in nude mice. We find that p53 promotes Mdm2-mediated ubiquitination and proteasomal degradation of the HIF-1α subunit of hypoxia-inducible factor 1 (HIF-1), a heterodimeric transcription factor that regulates cellular energy metabolism and angiogenesis in response to oxygen deprivation. Loss of p53 in tumor cells enhances HIF-1α levels and augments HIF-1-dependent transcriptional activation of the vascular endothelial growth factor (VEGF) gene in response to hypoxia. Forced expression of HIF-1α in p53-expressing tumor cells increases hypoxia-induced VEGF expression and augments neovascularization and growth of tumor xenografts. These results indicate that amplification of normal HIF-1-dependent responses to hypoxia via loss of p53 function contributes to the angiogenic switch during tumorigenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Apart from canonical HRE-mediated transcription, the HIF isoforms differentially modulate signaling pathways through interaction with proteins that do not contain PAS domains, such p53, the c-MYC proto-oncogene, β-catenin and the Notch intracellular domain (Fig. 2A) [11–15].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [11]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Intriguingly, p53 can also promote Mdm2-mediated degradation of HIF-1α (Ravi et al., 2000).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Ravi et al., 2000
The cited source says what the claim attributes to it.
In the citing paper
“It has been proposed that MDM2 can also ubiquitinate and degrade HIF-1α through the proteasome pathway”
From Stress Response of Glioblastoma Cells Mediated by miR-17-5p Targeting PTEN and the Passenger Strand miR-17-3p Targeting MDM2 (2012) · cites this paper as [56]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“which raises the possibility that miR-17 mediates cellular response to diverse stimuli by targeting closely related signaling pathways [56].”
From Stress Response of Glioblastoma Cells Mediated by miR-17-5p Targeting PTEN and the Passenger Strand miR-17-3p Targeting MDM2 (2012) · cites this paper as [56]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hershko, A., & Ciechanover, A. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.425 · Cited by 8,840
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212
Self-citationThe tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
Forsythe, J. A., Jiang, B.-H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., & Semenza, G. L. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4604 · Cited by 3,981
Self-citationKim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 1×
“…ligase and is itself a target for Ub-mediated degradation via its interaction with Mdm2 (Momand et al. 1992; Barak et al. 1993; Wu et al. 1993; Haupt et al. 1997; Honda et al. 1997; Kubbutat et al. 1997), this raised the possibility that HIF-1a is recruited to Mdm2 via its interaction with p53.”
Background
Flagged first, then by citations
7 of the 70 references couldn’t be matched to a known paper.
Research works printed but not linked: 3
- Kubbutat, 1997, Regulation of p53 stability by Mdm2., Nature, 387, 299, 10.1038/387299a0 · DOI · Paper page
- Ravi, 1998, p53-mediated repression of nuclear factor κ-B RelA via the transcriptional integrator p 300., Cancer Res., 58, 4531
- Zhong, 1999, Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases., Cancer Res., 59, 5830
Cited by
Sorted by citations
Items 801–900 of 967
Hypoxia, ROS, and HIF Signaling in I/R Injury: Implications and Future Prospects
Singh, M. K., Yun, H. R., Ranbhise, J. S., Han, S., Kim, S. S., & Kang, I. (2026) · Antioxidants · doi:10.3390/antiox15020153 · Cited by 9
Glioblastoma cell plasticity: A new paradigm in glioblastoma therapeutic resistance
Xiao, T., Wei, Z., & Wua, M. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189557 · Cited by 8
The E3 ubiquitin-protein ligase MDM2 is a novel interactor of the von Hippel–Lindau tumor suppressor
Falconieri, A., Minervini, G., Bortolotto, R., Piovesan, D., Lopreiato, R., Sartori, G., Pennuto, M., & Tosatto, S. C. E. (2020) · Scientific Reports · doi:10.1038/s41598-020-72683-3 · Cited by 7
Singh, V., Singh, R. K., Goswami, P., Manna, P. P., Baul, T. S. B., Mandal, A., Singh, A. K., & Koch, B. (2025) · Scientific Reports · doi:10.1038/s41598-025-89761-z · Cited by 7
Effect of p53 activation on experimental right ventricular hypertrophy
Veeroju, S., Mamazhakypov, A., Rai, N., Kojonazarov, B. K., Nadeau, V., Breuils‐Bonnet, S., Li, L., Weißmann, N., Rohrbach, S., Provencher, S., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0234872 · Cited by 6
Chen, X., Luo, C., Bai, Y., Yao, L., Shanzhou, Q., Xie, Y., Wang, S., Xu, L., Guo, X., Zhong, X., et al. (2022) · Critical Reviews in Eukaryotic Gene Expression · doi:10.1615/critreveukaryotgeneexpr.2022043444 · Cited by 7
The plant defensins PaDef and γ-thionin inhibit the endothelial cell response to VEGF
Falcón-Ruiz, E. A., López-Meza, J. E., & Ochoa‐Zarzosa, A. (2023) · Peptides · doi:10.1016/j.peptides.2023.171008 · Cited by 7
Jögi, A. (2015) · Springer eBooks · doi:10.1007/978-3-7091-1824-5_4 · Cited by 7
Heidarian, Y., Fasteen, T. D., Mungcal, L., Buddika, K., Mahmoudzadeh, N. H., Nemkov, T. G., D’Alessandro, A., & Tennessen, J. M. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102106 · Cited by 6
Hypoxia, Stem Cells and Cancer Stem Cells
Manian, M., Taherian, M., Nickho, H., Nejad, A. E., & Shaverdi, S. (2024) · Stem cell biology and regenerative medicine · doi:10.1007/978-3-031-74842-4_3 · Cited by 6
Yao, B., Ye, L., Li, Y., Bai, Y., Wei, X., Yang, Y., & Yao, D. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03563-8 · Cited by 6
Lam, G. C., & Sefton, M. V. (2014) · Tissue Engineering Part A · doi:10.1089/ten.tea.2014.0315 · Cited by 6
Protéger et sévir : p53, métabolisme et suppression tumorale
Albagli, O. (2015) · médecine/sciences · doi:10.1051/medsci/20153110013 · Cited by 8
Resistance of SMMC-7721 hepatoma cells to etoposide in hypoxia is reversed by VEGF inhibitor
Shi, S., Yuan, C., Zhuang, K.-Z., Liang, G., Yao, Z., WANG, D., Weng, Q., Cao, J., Luo, P., Zhu, H., et al. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3217 · Cited by 6
Angiogenesis Inhibitors for the Treatment of Lung Cancer
Nilsson, M. B., Hanrahan, E. O., & Heymach, J. V. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-184-0_24 · Cited by 6
Angiostatin and Endostatin: Angiogenesis Inhibitors in Blood and Stroma
Folkman, J. (2008) · Springer eBooks · doi:10.1007/978-0-387-71518-6_12 · Cited by 6
Development of a novel metastatic breast cancer score based on hyaluronic acid metabolism
El‐mezayen, H. A., Toson, E. A., Darwish, H., & Metwally, F. M. (2012) · Medical Oncology · doi:10.1007/s12032-012-0404-8 · Cited by 6
Chowdhury, I. H., Radonovich, M. F., Mahieux, R., Pise-Masison, C. A., Muralidhar, S., & Brady, J. N. (2003) · Journal of General Virology · doi:10.1099/vir.0.18753-0 · Cited by 6
Function of p53 in angiogenesis and oxidative stress in rheumatoid arthritis
Robat-Jazi, B., Farhadi, E., Mahmoudi, M., Jamshidi, A., Akhlaghi, M., & Vaziri, A. S. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01867-w · Cited by 7
Targeting mutant p53 in cancer: from mechanistic insights to therapeutic strategies
Wu, H. H., Leng, S., Eisenstat, D. D., Sergi, C. M., & Leng, R. P. (2026) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-026-00907-x · Cited by 6
Ruzzo, A., Graziano, F., Palladino, S., Fischer, N. W., Catalano, V., Giordani, P., Malkin, D. M., Tamburrano, T., Patriti, A., Petrelli, F., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae277 · Cited by 7
Fan, T., Feng, X., Yokota, A., Liu, W., Tang, Y., Yan, X., Xiao, H., Wang, Y., Deng, Z., Zhao, P., et al. (2021) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x2150021x · Cited by 5
Jensen, C. C., & Warfel, N. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00039-6 · Cited by 5
Herrera, J., Bensussen, A., García‐Gómez, M. L., Garay‐Arroyo, A., & Alvarez-Buylla, E. R. (2024) · npj Systems Biology and Applications · doi:10.1038/s41540-024-00469-8 · Cited by 5
Huang, H. B., Zhang, Z., Youngjian, X., & Jing-fang, S. (2003) · Current Medical Science · doi:10.1007/bf02829417 · Cited by 5
Hypoxia, angiogenesis, and colorectal cancer
Mizukami, Y., & Chung, D. C. (2007) · Current Colorectal Cancer Reports · doi:10.1007/s11888-007-0003-9 · Cited by 5
Bradbury, R., Jiang, W. G., & Cui, Y. (2015) · Biomarkers in Medicine · doi:10.2217/bmm.15.94 · Cited by 5
Zou, X., Zhang, L., Yuan, J., Yang, C., Wu, Z., Song, J., Zhu, W. P., Mao, Y. Q., & Liang, C. (2017) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13399 · Cited by 5
The Impact of Endothelial Transcription Factors in Sprouting Angiogenesis
Hofmann, M., & Heineke, J. (2018) · Springer eBooks · doi:10.1007/978-3-319-31215-6_38-1 · Cited by 5
Zhong, H., Wang, R., Kelavkar, U. P., Wang, C. Y., & Simons, J. W. (2014) · Cancer Medicine · doi:10.1002/cam4.227 · Cited by 5
Gui, Z., Zhao, L., Liu, S., & Zhang, L. (2025) · Cancer Nanotechnology · doi:10.1186/s12645-025-00341-2 · Cited by 4
p53: An Immune Ecosystem Manipulator
Nian, Z., Dou, Y., & Wei, H. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3628 · Cited by 4
Cao, Y. (2026) · Immunity & Inflammation · doi:10.1007/s44466-025-00021-1 · Cited by 5
Tam, H. H., Zhu, D., Ho, S. S. K., Vong, H. W., Wong, V. K. W., Mok, S. W.-F., & Wong, I. N. (2023) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1193362 · Cited by 4
The implication of serum HLA-G in angiogenesis of multiple myeloma
Wang, C., Su, N.-W., Hsu, K., Kao, C.-W., Chang, M., Chang, Y.-F., Lim, K., Chiang, Y., Chang, Y., Sung, M., et al. (2024) · Molecular Medicine · doi:10.1186/s10020-024-00860-5 · Cited by 4
Douglah, S., Khalil, R., Kanaan, R., Almeqbaali, M., Abdelmonem, N., Abdelmessih, M., Khairalla, Y., & Al-Rawi, N. H. (2024) · PeerJ · doi:10.7717/peerj.18486 · Cited by 4
Mandal, R. K., Yadav, S. S., & Panda, A. K. (2014) · Tumor Biology · doi:10.1007/s13277-014-2114-7 · Cited by 4
Deciphering the focal role of endostatin in Alzheimer’s disease
Kaur, D., Behl, T., Chigurupati, S., Sehgal, A., Singh, S., Sharma, N., Badavath, V. N., Vargas-De-La-Cruz, C. B., Bhatia, S., Al‐Harrasi, A., et al. (2021) · Environmental Science and Pollution Research · doi:10.1007/s11356-021-16567-7 · Cited by 4
Liu, H., Yu, J., Yang, L., He, P., & Li, Z. (2022) · Biochemical Genetics · doi:10.1007/s10528-022-10274-9 · Cited by 4
The Cycle Between Angiogenesis, Perfusion, and Hypoxia in Tumors
Dewhirst, M. W., Cao, Y., & Vlahovic, G. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-184-0_2 · Cited by 4
Regulators of Vascular Endothelial Growth Factor Expression in Cancer
Stoeltzing, O., & Ellis, L. M. (2006) · Kluwer Academic Publishers eBooks · doi:10.1007/1-4020-7847-1_3 · Cited by 4
Geng, Z., Zhu, J., Cao, J., Geng, J., Song, X., Zhang, Z., Bian, N., & Wang, Z. (2010) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2010.12.001 · Cited by 4
Hattori, K., Kajiyama, Y., & Tsurumaru, M. (2003) · Diseases of the Esophagus · doi:10.1111/j.1442-2050.2003.00351.x · Cited by 4
Bhattacharya, D., Singh, M. K., Chaudhuri, S., Datta, A., & Chaudhuri, S. (2016) · Journal of Cellular Physiology · doi:10.1002/jcp.25447 · Cited by 4
A Mathematical Model for the Onset of Avascular Tumor Growth in Response to the Loss of P53 Function
Levine, H. A., Smiley, M. W., Tucker, A. L., & Nilsen‐Hamilton, M. (2006) · Cancer Informatics · doi:10.1177/117693510600200022 · Cited by 4
Mahmoud, R., El‐Moslemany, R. M., Abou-Taleb, B. A., El-Mezayen, N. S., Awaad, A. K., & EL-Massik, M. A. E. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126485 · Cited by 3
Kealy, D., Ellerington, R., Bansal, S., Medeiros, J. J. F., Hawley, C. A., Zeng, A. G. X., Lukaszonek, J., West, K. A., Sinha, A. D., Caalim, G., et al. (2026) · Leukemia · doi:10.1038/s41375-025-02843-9 · Cited by 3
A dynamical model of apoptosis and its role in tumor progression
Laise, P., Fanelli, D., & Arcangeli, A. (2011) · Communications in Nonlinear Science and Numerical Simulation · doi:10.1016/j.cnsns.2011.09.014 · Cited by 3
Bignotti, E., Simeon, V., Ardighieri, L., Kuhn, E., Marchini, S., Califano, D., Cecere, S. C., Bugatti, M., Spina, A., Scognamiglio, G., et al. (2024) · International Journal of Cancer · doi:10.1002/ijc.35203 · Cited by 3
First-Line Combination of R-CHOP with the PDE4 Inhibitor Roflumilast for High-Risk DLBCL
Duque, A. E. D., Ferrari, P. S. S. M., Ethiraj, P., Jaafar, C., Qiu, Z., Holder, K. N., Butler, M. J., Huelgas‐Morales, G., Karnad, A. B., Dahia, P. L. M., et al. (2024) · Cancers · doi:10.3390/cancers16223857 · Cited by 3
Guo, H., Li, Y., Gu, J., Wang, Y., Liu, L., ZHANG, P., & Liu, Y. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.4571 · Cited by 3
A Narrative Review of the TP53 and Its Product the p53 Protein
Foroutan, B. (2023) · OBM Genetics · doi:10.21926/obm.genet.2302185 · Cited by 8
Yu, Z., Ran, G., Chai, J., & Zhang, E. E. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114727 · Cited by 4
The Hypoxia-Inducible Factor-1α in Angiogenesis and Cancer: Insights from the Drosophila Model
Tamamouna, V., & Pitsouli, C. (2018) · InTech eBooks · doi:10.5772/intechopen.72318 · Cited by 4
Bernstock, J. D., Ye, D. G., Gessler, F. A., Peruzzotti‐Jametti, L., Gilbert, M. R., Pommier, Y. G., Pluchino, S., Nakano, I., & Hallenbeck, J. M. (2017) · Matters · doi:10.19185/matters.201709000008 · Cited by 3
Teodoro, J. G., Evans, S. K., & Green, M. R. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0711-0_9 · Cited by 3
Hypoxia-Inducible Factor-1 Signaling System
Stroka, D., & Candinas, D. (2009) · Springer eBooks · doi:10.1007/978-3-642-00150-5_27 · Cited by 3
Therapeutic Strategies Based on Pharmacological Modulation of p53 Pathway
Gudkov, A. V. (2005) · Springer eBooks · doi:10.1007/0-387-30127-5_10 · Cited by 3
Cavalcante, L. D. S., Costa-Silva, T. A., de Souza, T. A., Ienne, S., & Monteiro, G. (2019) · Brazilian Journal of Microbiology · doi:10.1007/s42770-019-00154-7 · Cited by 3
Обрезан, А. Г., & Щербакова, Н. В. (2020) · Kardiologiia · doi:10.18087/cardio.2020.2.n985 · Cited by 3
Yang, C., Wang, Y., Zhao, J., & Zhang, Y. (2007) · Chinese Journal of Cancer Research · doi:10.1007/s11670-007-0136-z · Cited by 3
Hypoxia signalling in tumour angiogenesis
Knies, U. E., & Harris, A. L. (2000) · Emerging Therapeutic Targets · doi:10.1517/14728222.4.3.361 · Cited by 3
Antiangiogenic Strategies in Pancreatic Cancer
Bruns, C. J., Ellis, L. M., & Radinsky, R. (2006) · Springer eBooks · doi:10.1007/0-387-21600-6_34 · Cited by 3
Cancérogenèse. Accroissement des connaissances et évolution des concepts
Monier, R., & Tubiana, M. (2008) · ONCOLOGIE · doi:10.1007/s10269-008-0904-5 · Cited by 5
The anti-angiogenic and anti-vasculogenic mimicry effects of GN25 in endothelial and glioma cells
Wen, Z., Chang, L., Yang, S., Yu, C.-L., Tung, F.-Y., Kuo, H.-M., Lu, I., Wu, C., Shih, P., Chen, W.-F., et al. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2024.119799 · Cited by 2
Adaptive Significance of Non-coding RNAs: Insights from Cancer Biology
McDonald, J. F. (2025) · Molecular Biology and Evolution · doi:10.1093/molbev/msae269 · Cited by 2
Zhou, B., Zhao, K., Xue, J., Zhou, F., Duan, J., Niu, Y., & Wang, H. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70598 · Cited by 2
Ribonucleotide reductases in cancer: Mechanisms, clinical progress, and prospects
Chen, S., Huang, Y. H., Zhang, S., Zhang, J., Chen, C., Chen, G., & Zhou, D. (2025) · Cell investigation. · doi:10.1016/j.clnves.2025.100034 · Cited by 2
Pseudohypoxia induced by chemical pollutants: Biochemical evidence of environmental vulnerability
Hu, C., Tao, Z., Lin, Y., Chen, J., Ngeng, N. A., Aschner, M., Tinkov, A. A., & Lu, R. (2025) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2025.119243 · Cited by 2
Bhardwaj, S., Pandey, S., Ghosh, D. K., Sharma, T., & Jain, B. P. (2026) · World Journal of Experimental Medicine · doi:10.5493/wjem.v16.i1.115478 · Cited by 2
Molecular signaling and clinical implications in the human aging-cancer cycle
Rezaeian, A.-H., & Wei, W. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.08.003 · Cited by 2
Identify Non-mutational p53 Functional Deficiency in Human Cancers
Li, Q., Zhang, Y., Luo, S., Zhang, Z., Oberg, A. L., Kozono, D., Lu, H., Sarkaria, J. N., Ma, L., & Wang, L. (2024) · Genomics Proteomics & Bioinformatics · doi:10.1093/gpbjnl/qzae064 · Cited by 2
Therapeutic Strategies that Target the HIF System
Cook, K. M., & Schofield, C. J. (2008) · Springer eBooks · doi:10.1007/978-0-387-71518-6_32 · Cited by 2
Hypoxic Regulation of Angiogenesis by HIF-1
Charlesworth, P. J. S., & Harris, A. L. (2008) · Springer eBooks · doi:10.1007/978-0-387-71518-6_15 · Cited by 2
Ciblage pharmacologique de Mdm2 : bases biologiques et perspectives de radiosensibilisation
Chargari, C., Leteur, C., Ferté, C., Deberne, M., Lahon, B., Rivera, C., Bourhis, J., & Deutsch, É. (2011) · Cancer/Radiothérapie · doi:10.1016/j.canrad.2011.02.003 · Cited by 2
VEGF expression is inhibited by apigenin in human breast cancer cells
Jin, X.-Y., & Ren, C.-S. (2006) · Chinese Journal of Cancer Research · doi:10.1007/s11670-006-0306-4 · Cited by 2
Inhibition of HIF1α Signaling: A Grand Slam for MDS Therapy?
Chen, J., & Steidl, U. G. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1061 · Cited by 2
Eskandarion, M. R., Tizmaghz, Z., Andalib, B., Parsa, N. Z., Emami, S. A. H., Shahsiah, R., Oghabian, M. A., & Shirkoohi, R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.940678 · Cited by 2
The Impact of Endothelial Transcription Factors in Sprouting Angiogenesis
Hofmann, M., & Heineke, J. (2019) · Springer eBooks · doi:10.1007/978-3-319-33673-2_38 · Cited by 2
Principles of Antiangiogenic Therapy
Chau, C. H., & Figg, W. D. (2010) · Springer eBooks · doi:10.1007/978-1-60327-829-4_17 · Cited by 2
Gene and Protein Expression and Regulation in the Central Nervous System
Kubin, L. K., Gozal, D., & Czyzyk-Krzeska, M. (2002) · Lung biology in health and disease · doi:10.1201/9780203910504.ch5 · Cited by 2
TP53 Tumor Suppressor Gene: Structure and Function
Jerry, D. J., & Ozbun, M. A. (2002) · Elsevier eBooks · doi:10.1016/b0-12-227555-1/00180-5 · Cited by 2
Heymach, J. V., Zurita‐Saavedra, A., Kopetz, S., Cascone, T., Nilsson, M. B., & Guijarro, I. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm017.pub2 · Cited by 2
Kim, A., Huang, K., Johnson, J. L., Yaron, T. M., Wang, K., Cantley, L. C., Hu, Y., & Perrimon, N. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.10.681672 · Cited by 3
Yin, N., Li, X., Zhang, D., Qu, M., Pei, S., Chen, X., Zhang, X., & Zhang, J. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02367-8 · Cited by 1
Role of miRNAs, miR-135b-5p & miR-21-5p in metastasis of cervical cancer
Sultana, F., Chatterjee, N., Mukherjee, D., Panda, C. K., & Dutta, S. (2025) · The Indian Journal of Medical Research · doi:10.25259/ijmr_417_2025 · Cited by 1
EGLN1 (PHD2) role in tumor microenvironment: insights for therapeutic targeting
Verna, G., Fantini, V., Grieco, A., Ciarrocchi, A., & Sancisi, V. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01602-1 · Cited by 1
Interaction of HIF-1a with various cell death pathways in tumor immune microenvironment (TIME)
Varkiani, M. M., Faghihkhorasani, F., Moosavi, M., Habibi, R., Mirzaei, H., Karimi, N., Etemad, S., Karami, P., Osati, P., Aref, A. R., et al. (2026) · APOPTOSIS · doi:10.1007/s10495-025-02249-z · Cited by 6
Sánchez‐Castillo, A., Lommen, J. G. E., Consten, D., Savelkouls, K. G. M., Barbeau, L. M. O., Rouschop, K. M. A., Vooijs, M., & Kampen, K. R. (2026) · Cancer & Metabolism · doi:10.1186/s40170-026-00433-6 · Cited by 1
Myc and Control of Tumor Neovascularization
Sundaram, P., Dang, C. V., & Thomas‐Tikhonenko, A. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0711-0_8 · Cited by 1
Adhesion-Mediated Signalling in Cancer: Recent Advances and Mathematical Modelling
Crociani, O., Becchetti, A., Fanelli, D., & Arcangeli, A. (2014) · Biophysical Reviews and Letters · doi:10.1142/s1793048014300047 · Cited by 1
Hypoxia-Inducible Factor-1 Signaling System
Stroka, D., & Candinas, D. (2005) · Springer eBooks · doi:10.1007/3-540-27194-5_26 · Cited by 1
McDonnell, K., & Wellstein, A. (2007) · Springer eBooks · doi:10.1007/0-387-31056-8_19 · Cited by 1
Predicting p53-dependent cell transitions from thermodynamic models
Gautam, P., Ciuta, I., Teif, V. B., & Sinha, S. K. (2024) · The Journal of Chemical Physics · doi:10.1063/5.0225166 · Cited by 1
Regulation of Angiogenesis by Tumour Suppressor Pathways
Lefebvre, K. J., Assadian, S., El-Assaad, W., & Teodoro, J. G. (2013) · Springer eBooks · doi:10.1007/978-1-4614-3685-0_8 · Cited by 1
Pyruvate dehydrogenase kinase inhibition: Reversing the Warburg effect in cancer therapy
Bell, H. L., & Parkin, E. T. (2016) · International Journal of Cancer Therapy and Oncology · doi:10.14319/ijcto.42.15 · Cited by 1
P53 in Head and Neck Squamous Cell Carcinoma
Parameswaran, J., & Burtness, B. A. (2018) · Current cancer research · doi:10.1007/978-3-319-78762-6_9 · Cited by 1
Newer therapeutic approaches towards the management of diabetes mellitus: an update
Lin, H.-L., SHUKRI, F. N. M., YIH, E. S., SHA, G. H., JING, G. S., Jin, G. W., HOONG, C. W., YING, C. Q., Panda, B. P., Candasamy, M., et al. (2021) · Panminerva Medica · doi:10.23736/s0031-0808.19.03655-3 · Cited by 1
Tissue-Based Biomarkers of Tumor-Vascular Interactions
Akslen, L. A. (2022) · Springer eBooks · doi:10.1007/978-3-030-98950-7_2 · Cited by 1
Hypoxia and Senescence: Role of Oxygen in Modulation of Tumor Suppression
Eren, M. K. (2023) · Springer eBooks · doi:10.1007/978-981-99-0313-9_5 · Cited by 1
Metadata
- Authors
- Ravi, R., Mookerjee, B., Bhujwalla, Z. M., Sutter, C. H., Artemov, D., Zeng, Q., Dillehay, L. E., Madan, A., Semenza, G. L., & Bedi, A.
- Affiliations
- Johns Hopkins University (US)
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2000-01-01
- Volume
- 14
- Issue
- 1
- Pages
- 34-44
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W4294718043
- Semantic Scholar
- 5c0770cda1be256df47794076979768b0350af33
- Cited by
- 967
- References
- 70
- Citations by year
- 2026: 19 · 2025: 23 · 2024: 35 · 2023: 28 · 2022: 35 · 2021: 35 · 2020: 33 · 2019: 25 · 2018: 30 · 2017: 25 · 2016: 35 · 2015: 41 · 2014: 36 · 2013: 34 · 2012: 32
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Genes & Development (publishedVersion)
- Funders
- U.S. Department of Defense
- American Cancer Society
- National Institutes of Health
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- tumor angiogenesis, p53, hypoxia-inducible factor-1α, MDM2, ubiquitination, proteasomal degradation, vascular endothelial growth factor, hypoxia, neovascularization, tumor xenografts, angiogenic switch, tumor suppressor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
